GOJO takes action after FDA letter

US jan/san manufacturer GOJO responded swiftly to a warning letter from the US Food and Drug Administration (FDA) in January.


To continue reading this article, you must have a paid membership.

Join now from just £5

Existing paying members, please log in to access the full story.


If you are not a paying member, sign up now: